Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients.
In a prospective randomized trial, febrile granulocytopenic patients received either moxalactam plus piperacillin or moxalactam plus amikacin as initial empiric antimicrobial therapy. Most patients were also given prophylactic vitamin K. The overall response rates for the two regimens were similar (105 of 136, or 77 percent, for moxalactam plus piperacillin versus 107 of 136, or 79 percent, for moxalactam plus amikacin). For Pseudomonas aeruginosa infections, the response rate was better in patients receiving moxalactam plus amikacin (seven of nine versus one of five, p = 0.06); two patients treated with moxalactam plus piperacillin experienced relapse of P. aeruginosa bacteremia in association with the emergence of beta-lactam-resistant P. aeruginosa isolates. On the other hand, bacteremic enterococcal superinfections occurred in seven patients receiving moxalactam plus amikacin but in none given moxalactam plus piperacillin (p = 0.02). Serious side-effects were minimal with both regimens, and nephrotoxicity was less common in patients receiving moxalactam plus piperacillin (two of 136 versus six of 136, p = 0.28). There was no antibiotic-related hemorrhage. These results suggest that the overall efficacy and toxicity of moxalactam plus piperacillin and moxalactam plus amikacin are similar. Moxalactam/piperacillin therapy may be limited in certain patients by the emergence of beta-lactam-resistant P. aeruginosa, whereas enterococcal superinfections may complicate moxalactam/amikacin therapy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000150:complications*; D000583:Amikacin / Q000008:administration & dosage* / Q000009:adverse effects; D001421:Bacteria, Anaerobic; D001424:Bacterial Infections / Q000188:drug therapy / Q000209:etiology; D002648:Child; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D005260:Female; D005334:Fever / Q000188:drug therapy* / Q000209:etiology; D006094:Gram-Positive Bacteria; D006801:Humans; D007263:Infusions, Parenteral; D007612:Kanamycin / Q000031:analogs & derivatives*; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009070:Moxalactam / Q000008:administration & dosage* / Q000009:adverse effects; D010878:Piperacillin / Q000008:administration & dosage* / Q000009:adverse effects; D011552:Pseudomonas Infections / Q000188:drug therapy; D011897:Random Allocation; D013203:Staphylococcal Infections / Q000188:drug therapy
D007612:Kanamycin; D000583:Amikacin; D009070:Moxalactam; D010878:Piperacillin